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j Abstract Subtle structural brain abnormalities are
an established ﬁnding in ﬁrst-episode psychosis.
Nevertheless their relationship to the clinical course
of schizophrenia is controversially discussed. In a
multicentre study 45 ﬁrst-episode schizophrenia pa-
tients (FE-SZ) underwent standardized MRI scanning
and were followed up to 1 year. In 32 FE-SZ volu-
metric measurement of three regions of interests
(ROIs) potentially associated with disease course,
hippocampus, lateral ventricle and the anterior limb
of the internal capsule (ALIC) could be performed.
The subgroups of FE-SZ with good (12 patients) and
poor outcome (11 patients), deﬁned by a clinically
relevant change of the PANSS score, were compared
with regard to these volumetric measures. Multivari-
ate analysis of covariance revealed a signiﬁcant re-
duced maximal cross sectional area of the left ALIC in
FE-SZ with clinically relevant deterioration compared
to those with stable psychopathology. There were no
differences in the other selected ROIs between the two
subgroups. In conclusion, reduced maximal area of
ALIC, which can be interpreted as a disturbance of
fronto-thalamic connectivity, is associated with poor
outcome during the 1 year course of ﬁrst-episode
schizophrenia.
j Key words ﬁrst-episode schizophrenia Æ mag-
netic resonance imaging Æ disease course Æ outcome
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Structural brain abnormalities have been consistently
described in schizophrenic patients compared to
healthy controls [19, 27]. In a recent meta-analysis,
volumetricdeﬁcitsatdiagnosiswereseenintotalbrain
volume,inthehippocampus,incorticalgreymatter,in
Heschl’sgyrus,intheplanumtemporalandintemporal
grey matter, and in longitudinal studies continued
volumetric loss over time could be demonstrated in
these structures [22]. In addition, the lateral ventricles
were signiﬁcantly larger than normal at onset of the
illness and the ventricular volume tended to increase
signiﬁcantly in the disease course [22].
Only few studies focused on the predictive value
of brain morphology for the course of schizophrenia
in ﬁrst-episode patients and reported inconsistent
results [4, 5, 13, 16–18, 23]. It was observed that
hippocampal volume was associated with a higher
risk of relapse [16], greater ventricular expansion
was related to an unremitting course and poor out-
come [4, 5, 11], smaller temporal gray matter volume
was associated with persistence of hallucinations,
and more normal cerebral asymmetry was associated
with adequate social/vocational functioning and full
recovery [18]. Two other investigations could not
demonstrate a correlation between volumetric mea-
surement and treatment response [17] or 2-year
outcome [23].
The aim of the presented study was to investigate if
there is a difference in brain morphology focusing on
structures suggested in previous studies to be relevant
for the clinical course (hippocampus, lateral ventri-
cles) in a sample consisting of ﬁrst-episode patients
well characterized for the outcome over 1 year. Based
on previous ﬁndings of reduced internal capsule
volume and cross sectional area in families affected
with schizophrenia [25] and in ﬁrst-episode patients
[10], we decided to include volumetric measurement
of the anterior limb of the internal capsule (ALIC).
Method
j Subjects
The ﬁrst-episode study program [6] of the German Research Net-
work on Schizophrenia (GRNS) [26] consisted of an 8-week acute
treatment phase and a consecutive 2-year long-term treatment
phase (registered in ClinicalTrials.gov: NCT00159081). Between
2000 and 2004, 158 ﬁrst-episode patients, aged 18–55 years and
treated in inpatients departments of the participating centres, were
randomly assigned to double-blind, low-dose haloperidol or ris-
peridone. Drugs could be increased (up to 8 mg/day) or lowered
(minimum 1 mg/day) depending on symptoms or side effects as
indicated by the respective clinical global impressions (CGI) scales.
Concomitant medications were permitted throughout the trial,
except for additional antipsychotics or mood stabilizers. The results
of the clinical study have been published recently [7]. Patients were
diagnosed with schizophrenia according to DSM-IV by experienced
clinical psychiatrists using a standardized clinical interview (SCID;
German Version) [24]. Before entering the long-term treatment
study the diagnosis of schizophrenia was conﬁrmed by indepen-
dent experienced clinical psychiatrists.
A total of 75 patients of this long-term treatment phase ﬁrst-
episode sample participated in the MR-imaging study and were
recruited from the Psychiatry Departments of the Universities of
Bonn, Cologne, Du ¨sseldorf, Duisburg-Essen, Jena, Mainz, Mu-
nich, and Tu ¨bingen, as well as from the Central Institute of
Mental Health in Mannheim. Out of this sample only 45 patients
received standardized rating of psychopathology with the positive
and negative syndrome scale (PANSS) [9] at baseline and during
follow-up, and underwent magnetic resonance imaging (MRI) at
baseline due to a deﬁned protocol fulﬁlling the quality-criteria.
Exclusion criteria for the ﬁrst-episode long-term study and the
MRI study part were any psychiatric comorbidity (DSM-IV),
neurological diseases, contraindication for antipsychotic treat-
ment, suicidal behavior in previous history, mental retardation,
pregnancy, substance dependence, disorders which affect cerebral
metabolism, in addition to the usual exclusion criteria for MRI
(e.g. metal implants, cardiac pace makers). After a complete
description of the study, written informed consent was obtained
from each patient. The local ethics committees approved the
protocol, which is in accordance with the Declaration of Hel-
sinki.
From the MRI study sample we extracted 39 ﬁrst-episode pa-
tients, who received follow-up visits covering a period of at least
3 months up to 1 year (mean 46.6 ± 10.7 weeks). In this MR
sample volumetric measurement of all regions of interest could be
performed in 32 patients. We divided this patient sample in three
subgroups according to PANSS rating during the 1-year follow-up:
12 patients with stable psychopathology (good outcome; increase of
PANSS total score below 10% of baseline score, approximately 5
points), 9 patients with intermediate outcome (moderate worsen-
ing), and 11 patients with clinically relevant deterioration (bad
outcome; increase of PANSS total score above 40% of baseline
score, approximately 20 points).
The subgroup with good outcome did not show any clinically
relevant worsening of symptoms, presenting a stable course
(change of mean PANSS total score less than 4 points), while the
subgroup with bad outcome demonstrated a clinically relevant
increase of symptoms at least in one visit during the 1-year course,
predominantly in negative symptoms and general psychopathol-
ogy, (change of mean PANSS total score more than 40 points) (see
Table 1).
We compared the subgroups of good and bad outcome with
regard to volumetric measurement of three distinct brain regions:
hippocampus, lateral ventricles and the ALIC.
j Magnetic resonance imaging and measurements
Magnetic resonance imaging (MRI) was performed on Siemens and
Phillips 1.5 Tesla MR scanners with T1-weighted 3D data
(MPRAGE) sequences providing a spatial resolution of
1 · 1 · 1m m
3 (repetition time = 11.4 ms, echo time = 4.4 ms, ﬂip
angle = 15 ).
Manual area measurements for lateral ventricles, hippocampus
and ALIC were obtained using the ‘‘region of interest’’ tool
implemented in the software Analyze (version 3.0). Volumes of
ROIs were calculated by multiplying the outlined areas with slice
thickness, and relative volumes were calculated to adjust for dif-
ferences in total brain volumes. Intra- and interrater reliability was
measured in a subset of ten subjects. Intraclass correlation was
sufﬁciently high (ICC >0.7) [20]. The total brain volume, gray and
white matter volumes were determined using an automatic algo-
rithm programmed in MATLAB and SPM99 (Statistical Parametric
Mapping) [2].
The areas of the lateral ventricles were traced for each side
separately in coronal slices, and hippocampal contours were drawn
in the sagittal view following the borders described in the literature
[19]. The correctness of the outlines was controlled in the two other
views.
279The measurement of ALIC was performed as described previ-
ously [25] dividing the internal capsule into an anterior and pos-
terior part by a line bisecting the angle of internal capsule on
horizontal slices. ALIC was deﬁned medially by the caudate and
laterally by the lentiform nucleus. The ventral boundary was
determined by a line connecting the lateral edge of ventral part of
the caudate and the medial edge of the ventral part of the lentiform
nucleus. The ﬁrst slice included was the most inferior one com-
prising a detectable amount of white matter belonging to the
internal capsule. The last slice was the one inferior to the slice
which comprised the merging of internal capsule and the lamina
pallidi externa. The method of manual delineation required indi-
vidual optimization of contrast and brightness in each slice. ALIC
identiﬁcation was controlled for each slice in coronal and sagittal
orientation. Additionally, ALIC length and maximal cross sectional
area were measured, length as the sum of slices containing ALIC,
maximal cross section as maximal area of one particular slice
among all slices (see Fig. 1). In all cases the slice with maximal
cross sectional area was identical to the most superior slice directly
beneath the delta of merging internal capsule and lamina pallidi
externa.
j Statistics
Statistical analyses were performed with SPSS 10 for Windows. All
tests were two-tailed. Dependent variables were bilateral volumes of
the hippocampus and the ventricular system, and bilateral volumes,
maximal cross sectional area and length of the ALIC. Independent
variable was the outcome of the patients. Only the extreme groups
with good or bad outcome were included into the analysis.
Boxplots were examined to identify extreme values. Kolmogo-
rov–Smirnov tests were applied to test the assumption of normal
distribution. Since there were no signiﬁcant deviations from the
normality assumption, the general linear model (GLM) was per-
formed using a multivariate approach for left and right side mea-
surements separately for the blocks of dependent variables.
Independent factors outcome (good/bad) and gender and covariate
age were included into the model. Thus, all analyses were adjusted
for intervening inﬂuences of age and gender.
Results
The patient subgroups with good and poor outcome
did not differ in sociodemographic data (see Table 1).
First-episode patients who subsequently worsened
during the ﬁrst year of the illness revealed a signiﬁ-
cantly smaller maximal cross sectional area of the
ALIC compared to those patients with stable psy-
chopathology (GLM; multivariate: F = 4.5, df = 2, 17,
P = 0.028). Subsequent univariate tests showed that
this reduction was signiﬁcant on the left side ()19%,
F = 8.2, df = 1, 18, P = 0.010; see Fig. 2). Other
measurements of ALIC, as well as hippocampal and
lateral ventricular volumes were not signiﬁcantly re-
duced in patients with poor outcome compared to the
stable group (see Table 2).
We found no signiﬁcant correlations between the
cumulative doses of risperidone or haloperidol and
Fig. 1 Tracing of ALIC T1-weighted MR-image. The internal capsule is divided
into an anterior (ALIC) and posterior part (PLIC) by a line bisecting the angle of
internal capsule on horizontal slices. The right anterior limb of the internal
capsule (ALIC) is marked
Table 1 Clinical and sociodemographic data in the first-episode subgroups
FE-SZ stable (n = 12) FE-SZ bad outcome
(n = 11)
ANOVA
m SD m SD FP
Age (years) 30.40 9.42 33.18 12.87 0.31 0.58
Education (years) 11.60 3.03 12.11 2.62 0.15 0.70
Education of parents (years) 12.67 3.46 13.29 4.50 0.10 0.76
Baseline PANSS positive score 10.83 3.93 8.82 2.52 2.10 0.16
Baseline PANSS negative core 15.33 6.11 11.09 3.18 4.24 0.052
Baseline PANSS gen. score 27.92 7.38 23.09 5.72 3.03 0.096
Maximal PANSS positive score 11.33 3.87 13.73 5.10 1.63 0.22
Maximal PANSS negative score 16.58 6.32 21.64 3.93 5.19 0.033
Maximal PANSS gen. sum score 28.42 6.91 48.91 12.84 23.28 <0.0005
Diff. PANSS positive score 0.50 1.24 4.91 4.97 8.88 0.007
Diff. PANSS negative score 1.25 1.60 10.55 3.08 84.68 <0.0005
Diff. PANSS gen. score 0.50 1.00 25.82 11.11 62.07 <0.0005
FE-SZ stable FE-SZ bad outcome v
2 P
Gender (male/female), n 6/6 6/5 0.05 0.83
FE-SZ first-episode schizophrenic patients, Diff. difference, PANSS positive and negative syndrome scale, gen. general psychopathology, n sample size, m mean, SD
standard deviation, ANOVA analysis of variance, FF -statistics, P probability, v
2 Chi-Square-test
280the ALIC maximal cross sectional area in the total
group of patients and in the subgroups of schizo-
phrenic patients with stable psychopathology or
clinically relevant deterioration in the 1-year course.
The cumulative doses of risperidone and haloperidol
were not signiﬁcantly different in both subgroups
(df =1 ,F = 0.001; P = 0.98, oneway-ANOVA), and
the daily doses of risperidone and haloperidol in the
subgroups were comparable (FE-SZ stable psychopa-
thology: risperidone 4.3 ± 2.0 mg/day, haloperidol
3.0 ± 1.5 mg/day; FE-SZ poor outcome: risperidone
3.8 ± 1.3 mg/day, haloperidol 3.1 ± 1.6 mg/day).
While the educational level may have inﬂuenced
out results we repeated the analysis with education as
covariate. The results were similar, ﬁrst-episode pa-
tients with deterioration during the ﬁrst year of the
illness still presented with a signiﬁcantly smaller
maximal cross sectional area of the ALIC compared to
those patients with stable psychopathology (MAN-
COVA; P = 0.020).
Discussion
The main result of our study assessing the relation-
ship of brain morphology and clinical outcome in
ﬁrst-episode schizophrenia is the signiﬁcant reduced
maximal cross sectional area of the anterior limb of
the internal capsule (ALIC) in the subgroup of pa-
tients with clinical deterioration during the 1-year
course compared to patients with stable psychopa-
thology. There was no volumetric difference between
the two subgroups with regard to the other selected
regions of interest, hippocampus and lateral ventri-
cles.
While most prominent replicable brain abnor-
malities in schizophrenia are volume changes of the
grey matter (e.g. 19, 22, 27), some studies using voxel-
based morphometry revealed evidence for white
matter abnormalities, e.g. bilaterally in the frontal
lobe [14] or in the left temporal and frontal lobe of
schizophrenic patients with predominant negative
symptoms [21]. In addition, signiﬁcant decreases in
white matter density were detected in connecting
structures like the genu and truncus of the corpus
callosum, the right ALIC and the right anterior
commissure compared to healthy subjects [8].
Only a few studies assessed white matter changes
in schizophrenia that were hypothesis-driven using
the region of interest (ROI) approach. In the present
study we morphometrically assessed the hippocam-
pus and the lateral ventricles, whose volumetric
alterations are most consistently associated with the
course of the illness, as well as the anterior limb of the
internal capsule, a connecting white matter structure,
which has been found to exhibit decreased volumes
both in schizophrenia [28] and in unaffected ﬁrst-
degree relatives of schizophrenic patients [25].
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Fig. 2 Relative left ALIC maximal cross sectional area in first-episode
schizophrenia patients. ALIC, anterior limb of the internal capsule; FE-SZ,
first-episode schizophrenia patients; CI, confidence interval; max. cs, maximal
cross sectional; rel., relative
Table 2 Results of volumetric measurements
Region of interest FE-SZ stable (n = 12) FE-SZ bad outcome (n = 11) Diff (%) MANCOVA
m SD m SD Fd f P
Hippocampus volume left side (rel.) 0.00328 0.00044 0.00313 0.00034 )4.4 0.4 1, 17 0.23
Hippocampus volume right side (rel.) 0.00315 0.00055 0.00307 0.00037 )2.5 0.4 1, 17 0.45
Lateral ventricle volume left side (rel.) 0.01139 0.00467 0.00977 0.00528 )14.2 0.8 1, 18 0.38
Lateral ventricle volume right side (rel.) 0.01038 0.00466 0.00946 0.00507 )8.8 0.2 1, 18 0.64
ALIC volume left side(rel.) 0.00056 0.00011 0.00055 0.00010 )1.7 0.0 1, 18 1.00
ALIC volume right side(rel.) 0.00059 0.00010 0.00051 0.00010 )12.3 2.2 1, 18 0.15
ALIC max. cs. area left side (rel.) 0.0093 0.0014 0.0075 0.0013 )19.3 8.2 1, 18 0.010
ALIC max. cs. area right side (rel.) 0.0085 0.0015 0.0079 0.0013 )6.9 0.8 1, 18 0.38
ALIC length left side (rel.) 0.0923 0.0128 0.0945 0.0116 2.5 0.6 1, 18 0.44
ALIC length right side (rel.) 0.0930 0.0108 0.0955 0.0120 2.7 0.8 1, 18 0.39
Total brain volume (absolute, cm
3) 1136.5 116.6 1133.1 103.2 1.4 0.1 1, 18 0.73
FE-SZ first-episode schizophrenic patients, Diff. difference, n sample size, m mean, SD standard deviation, FF -statistics, df degrees of freedom, P probability, rel.
relative, max. cs. maximal cross sectional, MANCOVA multivariate analysis of covariance, F, P for factor subgroup
281Out of the three mentioned structures, in our
study only the left maximal cross sectional area of
the anterior limb of the internal capsule was asso-
ciated with the clinical course in ﬁrst-episode
schizophrenia. In this sample of ﬁrst-episode pa-
tients those with poor outcome (high increase of
positive symptoms) showed a reduced maximal cross
sectional area of the ALIC on the left side compared
to those with good outcome. However, when left and
right ALIC maximal cross sectional areas of both
subgroups are compared, there is an inverse rela-
tionship. In the good outcome group the mean left
ALIC maximal cross sectional area is larger than the
right one, and in the bad outcome group it is the
other way round. This inverse relationship may be at
least in part responsible for the signiﬁcant difference
between the subgroups. This may point towards a
different asymmetry or shape of this structure in the
subgroups. Nevertheless we can not rule out the
possibility that the left ALIC maximal cross sectional
area in the patients with good outcome group may
be disproportionately large in our sample.
The ALIC is a very important connecting structure
linking the frontal cortex to subcortical structures
through the medial [15] and the basolateral limbic
circuit [12]. Abnormalities in the ALIC can thus be
taken as measure for disturbances in the frontotha-
lamic connectivity that is discussed to be relevant for
the pathophysiology of schizophrenia [1].
Interestingly, a recent study shows that a reduced
area of the ALIC in dorsal MRI slices was associated
with poor outcome based on longitudinal analysis of
self-care deﬁcits in chronic schizophrenia [3]. The
authors suggest disruption of internal capsule ﬁbers
in poor-outcome patients with schizophrenia, which
is supported by the results of our study. The re-
duced maximal cross sectional area measured in our
investigation corresponds to the reduced ALIC area
in dorsal MRI slices of the cited study. Additionally,
our results indicate that reduced white ﬁber struc-
tures in this area might increase the risk not only
for a poor outcome in chronic schizophrenic pa-
tients, but also increase the vulnerability for the
onset of schizophrenic psychosis and an unfavour-
able course in ﬁrst-episode schizophrenia. To our
knowledge this study is the ﬁrst one investigating
the relevance of white matter structures, especially
the ALIC, for the course of ﬁrst-episode schizo-
phrenia.
There are several limitations of our study. We were
not able to control for the inﬂuence of possible con-
founding factors determining poor outcome, e.g.
psychosocial circumstances or neurocognitive func-
tion. Secondly, the follow-up observational period
without any intermediate anchor point may be too
long to document the disease course adequately.
Medication could serve as a confounding factor in
structural neuroimaging. While the cumulative and
daily doses of risperidone and haloperidol were low
and similar distributed in both subgroups we do not
assume a relevant inﬂuence of antipsychotic medica-
tion on our volumetric results or on clinical outcome,
for instance by the induction of secondary negative
symptoms.
In conclusion our ﬁnding of reduced internal
capsule size in patients with bad outcome supports
the dysconnectivity concept of schizophrenia [28] and
points towards disturbances in the striato-thalamo-
cortical neuronal circuit and abnormalities in related
structures.
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